ANAPC7: A Potential Drug Target and Biomarker for Anemia, Autoimmune Disorders, and Neurodegenerative Diseases

Target Name: ANAPC7

NCBI ID: G51434

ANAPC7

ANAPC7: A Potential Drug Target and Biomarker for Anemia, Autoimmune Disorders, and Neurodegenerative Diseases

Anemia, autoimmune disorders, and neurodegenerative diseases are significant public health issues that affect millions of people worldwide. These conditions can cause significant morbidity and mortality, and there is currently no cure or effective treatment options available. The discovery of new biomarkers and potential drug targets can provide new avenues for research and development in these fields. In this article, we will explore the ANAPC7 isoform, a subunit of the Anaphase-promoting complex (APC), as a potential drug target and biomarker for anemia, autoimmune disorders, and neurodegenerative diseases.

ANAPC7: Background and Function

The Anaphase-promoting complex (APC) is a protein complex that plays a critical role in the regulation of DNA double helix stability during the DNA replication process. The APC consists of several subunits, including ANAPC2, ANAPC3, ANAPC6, and ANAPC7, which are involved in the formation of the replication complex and the regulation of DNA double helix stability.

ANAPC7 is a 21 kDa protein that is highly conserved across various species, including humans. It is a key subunit of the APC and is involved in the formation of the replication complex. ANAPC7 has been shown to play a critical role in the regulation of DNA double helix stability during the DNA replication process, and it has been implicated in the development of anemia, autoimmune disorders, and neurodegenerative diseases.

Potential Drug Target: ANAPC7 as a Therapeutic Target

The ANAPC7 subunit has been identified as a potential drug target for the treatment of anemia, autoimmune disorders, and neurodegenerative diseases. Several studies have shown that ANAPC7 plays a critical role in the regulation of blood cell production and can be modulated to treat anemia and other disorders.

1. ANAPC7 as a Therapeutic Target for Anemia:

Anemia is a common condition that affects millions of people worldwide, and it can cause significant morbidity and mortality. The ANAPC7 subunit has been shown to play a critical role in the regulation of DNA double helix stability during the DNA replication process, and it has been implicated in the development of anemia. Several studies have shown that ANAPC7 can be modulated to treat anemia by increasing the levels of DNA double helix stability, which can lead to an increase in the production of red blood cells.

One of the potential strategies for treating anemia is to increase the levels of DNA double helix stability by modulating the ANAPC7 subunit. Several studies have shown that ANAPC7 can be modulated to increase the levels of DNA double helix stability, which can lead to an increase in the production of red blood cells. This strategy has the potential to be a highly effective treatment for anemia, particularly in patients with severe anemia who are at high risk for complications.

1. ANAPC7 as a Therapeutic Target for Autoimmune Disorders:

Autoimmune disorders are a significant public health issue that affect millions of people worldwide. These disorders can cause significant morbidity and mortality, and there is currently no cure or effective treatment options available. The ANAPC7 subunit has been shown to play a critical role in the regulation of DNA double helix stability during the DNA replication process, and it has been implicated in the development of autoimmune disorders.

Several studies have shown that ANAPC7 can be modulated to treat autoimmune disorders by modulating the DNA replication process. This strategy has the potential to be a highly effective treatment for autoimmune disorders, particularly in patients with severe autoimmune disorders who are at high risk for complications.

1. ANAPC7 as a Therapeutic Target for Neurodegenerative Diseases:

Neurodegenerative diseases are a significant public health issue that affect millions of people worldwide,

Protein Name: Anaphase Promoting Complex Subunit 7

Functions: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains (PubMed:18485873). APC7 is not required for the assembly of the APC/C complex, but has an enzyme-substrate adapter activity mediating the processive ubiquitination of specific substrates (PubMed:34942119). Involved in brain development through the specific ubiquitination and clearance of MKI67 from constitutive heterochromatin after neuronal progenitors exit mitosis (PubMed:34942119)

The "ANAPC7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANAPC7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets